Source link : https://www.newshealth.biz/health-news/drugmaker-pulls-trodelvys-bladder-cancer-approval/
Sacituzumab govitecan’s (Trodelvy) accelerated approval in urothelial cancer will be voluntarily withdrawn, Gilead Sciences announced on Friday. The decision was made in consultation with the FDA and does not affect the antibody-drug conjugate’s other indications, the company said. A Trop-2-directed antibody, sacituzumab govitecan was granted accelerated approval for urothelial cancer in 2021 — for patients […]
Author : News Health
Publish date : 2024-10-18 18:01:05
Copyright for syndicated content belongs to the linked Source.